Lytix Biopharma AS - New share capital registered
Oslo, Norway, 23 December 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
0,488€
-0,20%
Echtzeit-Aktienkurs Lytix Biopharma AS
Bid:
Ask:
Nachrichten zur Lytix Biopharma AS Aktie
Lytix Biopharma AS: Private placement and retail offer via PrimaryBid successfully completed
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG,…
Lytix Biopharma – Lytix launches Retail Offering via Primary Bid and Nordnet, in parallel with private placement
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG,…
Lytix Biopharma AS: Contemplated private placement and retail offer via PrimaryBid
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG,…
Lytix Biopharma Q3 2024: Positive clinical results and strategic advancements strengthen path to commercialization
Oslo, 19 November 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
Lytix Biopharma Q2 and H1 2024 results: Significant clinical advancements take Lytix Biopharma closer to commercialization
Oslo, 29 August 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
Lytix Biopharma: Lytix’s licensing partner, Verrica Pharmaceuticals, to release preliminary topline results from their Phase II trial of LTX-315 for the treatment of basal cell carcinoma on August 14
Oslo, August 06, 2024. Lytix Biopharma announces that its licensing partner, Verrica Pharmaceuticals, will host an investor call to report…
Lytix Biopharma Q1 2024 results - Promising clinical progress with important upcoming milestones
Oslo, 30 May 2024. Lytix Biopharma (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company dedicated to being part of…
Lytix Biopharma: Invitation to presentation of first quarter 2024 results, Thursday 30 May 2024
Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its first quarter 2024 results on…
Lytix Biopharma – Minutes of Ordinary General Meeting
Oslo, Norway, May 14, 2024 – The Ordinary General Meeting of Lytix Biopharma AS ("Lytix" or the "Company") was held…
Lytix Biopharma AS - New share capital registered
Oslo, Norway, 13 May 2024: Reference is made to the stock exchange announcements published by Lytix Biopharma AS ("Lytix" or…
Correction in the notice of Annual General Meeting in Lytix Biopharma AS
Oslo, 3 May 2024: Reference is made to the stock exchange announcement published on 30 April 2024 where Lytix Biopharma…
Lytix Biopharma AS: Annual Report for 2023
Oslo, Norway, April 30, 2024 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces…
Lytix Biopharma AS – Mandatory notification of trade by Primary Insiders and close associates
Oslo, Norway, 26 April 2024: Reference is made to the stock exchange announcement published by Lytix Biopharma AS ("Lytix" or…
Lytix Biopharma AS – Share issue pursuant to board authorisation
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Lytix Biopharma AS – Minutes of extraordinary general meeting and final results of share offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Lytix Biopharma announces approval of the Phase II study in early-stage skin cancer (melanoma) representing a significant commercial opportunity
Oslo, 25 April 2024. Lytix Biopharma announces that the Norwegian Medical Products Agency has approved the clinical trial application for…
Lytix Biopharma AS – Preliminary results in the share offering
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES,…
Lytix Biopharma presents third quarter 2023 results
Oslo, 09 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, today releases its…
Lytix Biopharma presenting at major investor conferences in London and Stockholm in November
Oslo, 8 November 2023. Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that Dr…
Lytix Biopharma: Presentation of third quarter 2023 results, November 9
Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023
Oslo, 23 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma to host webcast after release of preliminary data from ATLAS-IT-05
Oslo, 20 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’
Oslo, 17 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Neoadjuvant study with LTX-315 in early-stage melanoma patients to be presented at the 15th Nordic melanoma meeting
Oslo, 9 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial
Oslo, 28 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma announces that Verrica Pharmaceuticals Inc. will present clinical results from their ongoing Phase II clinical study with LTX-315 (VP-315) at the AAD 2023 Innovation Academy Meeting
Oslo, 3 August 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma announces presentation of interim data from ATLAS-IT-05 study at ESMO 2023.
Oslo, 20 July 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma presents first quarter 2023 results
Oslo, 11 May 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma appoints new Chairman of the Board
Oslo, Norway, April 18, 2023 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces…
Lytix Biopharma: Annual Report for 2022
OSLO, Norway, March 30, 2023 /PRNewswire/ -- Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company,…
Lytix Biopharma: Annual Report for 2022
Oslo, Norway, March 30, 2023 – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces…
Lytix Biopharma presents fourth quarter and second half 2022 results
OSLO, Norway, Feb. 16, 2023 /PRNewswire/ -- Lytix Biopharma ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, today releases…
Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February
OSLO, Norway, Feb. 9, 2023 /PRNewswire/ -- Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will…
Lytix Biopharma: Invitation to presentation of fourth quarter and second half 2022 results, Thursday 16 February
Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a Norwegian immuno-oncology company, will release its fourth quarter and second half…